Drug Profile
Research programme: cancer immunotherapies - GlaxoSmithKline/M.D. Anderson Cancer Center
Alternative Names: IACS-9779Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer GSK; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in USA
- 29 Mar 2019 Preclinical trials in Cancer in USA (unspecified route)
- 29 Mar 2019 Pharmacodynamics data from in vitro and in vivo studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)